Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Duchenne muscular dystrophy (DMD)
Biotech
FDA skips AdComm for Sarepta's DMD therapy, sets decision date
The FDA won’t be holding an advisory panel meeting for Sarepta’s SRP-9001, which could become the first gene therapy for Duchenne muscular dystrophy.
Gabrielle Masson
Feb 28, 2023 8:00pm
EMA gives support to Duchenne trial simulation platform
Jan 26, 2023 5:00am
Fresh from Vertex payday, Entrada's DMD plans derailed by FDA
Dec 20, 2022 8:45am
Sarepta preps $1.2B war chest for DMD gene therapy
Nov 3, 2022 10:02am
Santhera loses interest in pulmonary drug to focus on DMD
Oct 31, 2022 10:25am
Sarepta, freed from phase 2 clinical hold, picks up momentum
Sep 6, 2022 11:28am